In the article titled “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway” [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).